NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
October 16 2022 - 4:30PM
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a
conference call and live webcast on Monday, October 17, 2022 at
8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety
results from its CATALINA Phase 2 trial of NGM621 in patients with
geographic atrophy secondary to age-related macular degeneration.
To access the live webcast and slides, please visit the
“Investors & Media” section of NGM Bio’s website
at https://ir.ngmbio.com/. The webcast will be archived for 30
days.
About NGM Bio
NGM Bio is focused on discovering and developing novel,
life-changing medicines for people whose health and lives have been
disrupted by disease. The company’s biology-centric drug discovery
approach aims
to seamlessly integrate interrogation of complex
disease-associated biology and protein engineering expertise to
unlock proprietary insights that are leveraged to generate
promising product candidates and enable their rapid advancement
into proof-of-concept studies. As explorers on the frontier of
life-changing science, NGM Bio aspires to operate one of the most
productive research and development engines in the
biopharmaceutical industry. All therapeutic candidates in the NGM
Bio pipeline have been generated by its in-house discovery engine,
always led by biology and motivated by unmet patient need. Today,
the company has seven programs in clinical
development, including four in Phase 2 or 2b
studies, including the recently completed NGM621 CATALINA
trial, across three therapeutic areas:
cancer, retinal diseases and liver and
metabolic diseases. Visit us at www.ngmbio.com for more
information.
Investor
Contact:Brian Schoelkopfir@ngmbio.com |
Media
Contact:Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jul 2024 to Aug 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Aug 2023 to Aug 2024